Hansoh Pharmaceutical Group Co. Ltd. has announced that its HS-10510 tablets, a Category 1 innovative drug developed in-house, have received Clinical Trial Approval from the National Medical Products Administration of China. The clinical trials will investigate the tablets' efficacy for treating primary hypercholesterolemia and mixed dyslipidemia. This development marks a significant step in the company's ongoing efforts to advance its pharmaceutical innovations. The announcement was made by the board of directors, led by Chairlady Zhong Huijuan, on May 29, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.